We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious... Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. Show more
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief...
Integration of AL102 and IM-1021 completed Topline data for Phase 3 RINGSIDE trial of AL102 expected in second half of 2025 IM-1021 and IM-3050 IND submissions expected in first quarter of 2025...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Kinney Horn as Chief...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.05 | -0.350385423966 | 14.27 | 15.45 | 13.515 | 913991 | 14.03452935 | CS |
4 | -0.06 | -0.420168067227 | 14.28 | 16.79 | 13.515 | 833001 | 14.58904097 | CS |
12 | -10.09 | -41.5055532703 | 24.31 | 30.958 | 13.515 | 741321 | 18.58417824 | CS |
26 | 6.3 | 79.5454545455 | 7.92 | 30.958 | 6.93 | 648833 | 18.41817439 | CS |
52 | 8.67 | 156.216216216 | 5.55 | 30.958 | 4.5 | 399362 | 16.34934791 | CS |
156 | -3.79 | -21.0438645197 | 18.01 | 30.958 | 2.09 | 209920 | 15.56298481 | CS |
260 | -1.44 | -9.19540229885 | 15.66 | 63.78 | 2.09 | 200355 | 17.48767575 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions